At the 2019 San Antonio Breast Cancer Symposium, researchers reported findings from clinical trials that could lead to new treatment options for some patients with metastatic breast cancer. These studies included:
• HER2CLIMB: This phase III study looked at the combination of the experimental drug tucatinib, trastuzumab (Herceptin®) and capecitabine (Xeloda®) in HER2-positive MBC patients previously treated with Herceptin, pertuzumab (Perjeta®), and T-DM1 (Kadcyla®). The study showed the new regimen extended survival outcomes longer than Herceptin® and Xeloda® alone, including in patients with brain metastases.
• SOPHIA: Updated data from the phase III SOPHIA trial, which compared margetuximab and chemotherapy to trastuzumab (Herceptin®) and chemotherapy in patients with HER2-positive metastatic breast cancer previously treated with other HER2-targeted drugs showed margetuximab improved progression-free survival.
• DESTINY: This phase II clinical trial looked at the investigational drug trastuzumab deruxtecan (T-DXd; DS-8201) in patients with advanced HER2-positive breast cancer who had already tried many other treatments. It showed a response rate of almost 61%.
Below you can learn more about these studies as well as other findings that are important to the MBC community.
HER2CLIMB Trial — Tucatinib
- Clinical Care Options (slide presentation): HER2CLIMB Trial
- Medpage Today (video): SABCS Expert Roundtable Episode 1: A discussion on the practice-changing findings on HER2-positive disease
- Targeted Oncology: Tucatinib Granted FDA Breakthrough Designation for Treatment of Metastatic HER2-Positive Breast Cancer
SOPHIA Trial — Margetuximab
- Clinical Care Options (slide presentation): SOPHIA Trial
- OncLive (video): Updated Data From the SOPHIA Trial in HER2+ Metastatic Breast Cancer
- OncLive: Margetuximab Update Elucidates Clinical Benefit in HER2+ Metastatic Breast Cancer
- Targeted Oncology: Margetuximab Demonstrates Modest OS Benefit in HER2+ Metastatic Breast Cancer
- OncLive: FDA Approval Sought for Margetuximab in HER2+ Metastatic Breast Cancer
Destiny Trial — Trastuzumab Deruxtecan (DS-8201a; T-DXd)
- Clinical Care Options (slide presentation): DESTINY-Breast01 Trial
- Targeted Oncology: Responses Observed With T-DXd May Change Standard of Care in Advanced HER2+ Breast Cancer
- OncLive: FDA Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer
PEARL Trial — endocrine therapy with palbociclib
- Clinical Care Options (slide presentation): PEARL Trial
- Cancer Therapy Advisor: Endocrine Therapy With Palbociclib: No PFS Advantage in Metastatic Breast Cancer
- Medpage Today (video): SABCS Expert Roundtable Episode 3: The Pearl and Coralleen trials
Other Trials (slide presentations)
- Clinical Care Options: Circulating Tumor DNA Testing to Direct Targeted Therapies in Patients with Advanced Breast Cancer
- Clinical Care Options: Neratinib With or Without Fulvestrant for HER2 Mutation–Positive Advanced Breast Cancer
- Clinical Care Options: The Effects of Trastuzumab Deruxtecan in HER2-Expressing MBC
- Clinical Care Options: Impact of Neratinib on CNS Metastases in Patients With HER2-Positive MBC
2019 SABCS Coverage by Breastcancer.org
- FDA Approves Enhertu for Unresectable or Pretreated Metastatic HER2-Positive Breast Cancer
- Is Oral Paclitaxel Better Than IV Paclitaxel for Metastatic Breast Cancer?
- Experimental Tucatinib Improves Survival in Metastatic HER2-Positive Breast Cancer, May Be New Standard of Care
- SABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?
- Top News at 2019 SABCS – Heard in the Halls: Voices From the 2019 SABCS
- GRASP: Empowering Patients With Knowledge – Heard in the Halls: Voices From the 2019 SABCS
- Why Sexual Health Is Crucial for People With Metastatic Breast Cancer – Heard in the Halls: Voices From the 2019 SABCS
- Mets, Sex, and Side Effects – Heard in the Halls: Voices From the 2019 SABCS
- Beneath the Breast – Heard in the Halls: Voices From the 2019 SABCS
2019 SABCS Coverage by Living Beyond Breast Cancer (LBBC)
- HER2-Targeted Therapies Presented at SABCS Move Quickly Through FDA Approval
- Adding Tucatinib to Third-Line Treatment Leads to Longer Overall Survival in People with Metastatic, HER2-Positive Breast Cancer
- Trastuzumab Deruxtecan Shows High Response Rates in Phase II Trial
- Interview with Hope Rugo, MD, from SABCS (video)
- Oral paclitaxel, update from SABCS
SABCS and Patient Advocacy
- Cancer Today: Cancer Patient Advocates Find Strength in Numbers
- Living Beyond Breasts Cancer: Hearing and Being Heard at San Antonio Breast Cancer Symposium 2019
- Living Beyond Breasts Cancer: Driving the Point Home: Taking Lessons From National Conferences to Your Local Community NEW!
Last Modified on February 10, 2021